ALGS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ALGS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Aligos Therapeutics's interest expense for the three months ended in Mar. 2024 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Aligos Therapeutics's Operating Income for the three months ended in Mar. 2024 was $ -22.05 Mil. Aligos Therapeutics's Interest Expense for the three months ended in Mar. 2024 was $ 0.00 Mil. GuruFocus does not calculate Aligos Therapeutics's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
The historical data trend for Aligos Therapeutics's Interest Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aligos Therapeutics Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Interest Expense | Get a 7-Day Free Trial | - | - | - | - | - |
Aligos Therapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Interest Expense | Get a 7-Day Free Trial | - | - | - | - | - |
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aligos Therapeutics (NAS:ALGS) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Aligos Therapeutics's Interest Expense for the three months ended in Mar. 2024 was $0.00 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-22.05 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $7.21 Mil.
Aligos Therapeutics's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as
GuruFocus does not calculate Aligos Therapeutics's interest coverage with the available data. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Aligos Therapeutics Inc has enough cash to cover all of its debt. Its financial situation is stable.
Roche Finance Ltd | 10 percent owner | C/O HOFFMAN LA ROCHE, 124 GRENSACHERSTRASSE CH 4002, BASEL SWITZERLAND V8 |
Roche Holding Ltd | 10 percent owner | ROCHE HOLDING, LTD., GRENZACHERSTRASSE 124, BASEL V8 CH-4070 |
Carole Nuechterlein | director | C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 160, BANNOCKBURN IL 60015 |
Matthew W. Mcclure | officer: Chief Medical Officer | C/O ALIGOS THERAPEUTICS, INC., 1 CORPORATE DRIVE, 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080 |
Bridget A Martell | director | C/O POINT BIOPHARMA GLOBAL INC., 4850 WEST 78TH STREET, INDIANAPOLIS IN 46268 |
James Paul Scopa | director | 601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO CA 94080 |
Thomas Woiwode | director | ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
Vivo Capital Fund Viii, L.p. | 10 percent owner | 505 HAMILTON AVENUE, SUITE 200, PALO ALTO CA 94301 |
Novo Holdings A/s | 10 percent owner | TUBORG HAVNEVEJ 19, HELLERUP G7 2900 |
Versant Venture Capital Vi, L.p. | 10 percent owner | ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
Vivo Capital Surplus Fund Viii, L.p. | 10 percent owner | 505 HAMILTON AVENUE, SUITE 200, PALO ALTO CA 94301 |
Julian A. Symons | officer: See Remarks | C/O ALIGOS THERAPEUTICS, INC., ONE CORPORATE DRIVE, 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080 |
Leonid Beigelman | director, officer: President | C/O ALIGOS THERAPEUTICS, INC., ONE CORPORATE DRIVE, 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080 |
Lucinda Y. Quan | officer: See Remarks | C/O ALIGOS THERAPEUTICS, INC., ONE CORPORATE DRIVE, 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080 |
Lawrence Blatt | director, officer: Chief Executive Officer |
From GuruFocus
By Marketwired • 09-21-2023
By Marketwired • 07-27-2023
By GlobeNewswire GlobeNewswire • 05-24-2023
By GuruFocus Research • 11-02-2023
By sperokesalga sperokesalga • 02-28-2023
By Marketwired • 07-19-2023
By Marketwired • 10-26-2023
By sperokesalga sperokesalga • 03-29-2023
By sperokesalga sperokesalga • 06-07-2023
By sperokesalga sperokesalga • 05-24-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.